Wedbush Decreases Earnings Estimates for iTeos Therapeutics

iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Equities researchers at Wedbush decreased their Q2 2025 earnings estimates for iTeos Therapeutics in a research report issued to clients and investors on Monday, July 21st. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($1.56) per share for the quarter, down from their previous forecast of ($1.48). Wedbush currently has a "Outperform" rating and a $10.50 target price on the stock. The consensus estimate for iTeos Therapeutics' current full-year earnings is ($3.49) per share. Wedbush also issued estimates for iTeos Therapeutics' Q3 2025 earnings at ($2.07) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($4.60) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.26) EPS.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last posted its quarterly earnings results on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14.

ITOS has been the topic of a number of other reports. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $12.00 price objective (down from $13.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 28th. Leerink Partners reaffirmed a "market perform" rating and issued a $9.00 price objective (down from $47.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. JPMorgan Chase & Co. lowered shares of iTeos Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the company from $15.00 to $8.00 in a research note on Tuesday, May 13th. Leerink Partnrs lowered shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 14th. Finally, HC Wainwright lowered shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, May 14th. Six analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $15.64.

iTeos Therapeutics Stock Up 0.2%

NASDAQ:ITOS traded up $0.02 during trading hours on Thursday, reaching $10.17. The company had a trading volume of 1,048,505 shares, compared to its average volume of 1,411,017. The firm has a market cap of $389.21 million, a price-to-earnings ratio of -3.35 and a beta of 1.49. The business's 50-day simple moving average is $9.88 and its two-hundred day simple moving average is $8.00. iTeos Therapeutics has a twelve month low of $4.80 and a twelve month high of $18.13.

Insider Activity

In related news, major shareholder Bioventures 2018 L.P. Mpm sold 630,191 shares of the firm's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $8.06, for a total transaction of $5,079,339.46. Following the transaction, the insider directly owned 2,108,594 shares of the company's stock, valued at $16,995,267.64. This trade represents a 23.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director David Hallal sold 38,228 shares of the firm's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $10.24, for a total transaction of $391,454.72. The disclosure for this sale can be found here. Insiders sold 1,939,307 shares of company stock valued at $16,202,116 over the last ninety days. Company insiders own 12.50% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Strs Ohio bought a new stake in iTeos Therapeutics in the first quarter worth about $31,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in iTeos Therapeutics in the fourth quarter worth about $42,000. CWM LLC raised its position in iTeos Therapeutics by 428.7% in the first quarter. CWM LLC now owns 8,554 shares of the company's stock worth $51,000 after acquiring an additional 6,936 shares during the period. Paloma Partners Management Co bought a new stake in iTeos Therapeutics in the first quarter worth about $65,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in iTeos Therapeutics in the first quarter worth about $67,000. 97.16% of the stock is owned by institutional investors.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.